- Home
- GECC vs QNCX Comparison
GECC vs QNCX Comparison
Compare GECC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GECC | QNCX |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 17.5M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GECC | QNCX |
|---|---|---|
| Price | $5.23 | $30.00 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 59.6K | 15.7K |
| Earning Date | 05-12-2026 | 04-10-2026 |
| Dividend Yield | ★ 22.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $0.08 |
| 52 Week High | $9.88 | $35.41 |
Technical Indicators
Market Signals| Indicator | GECC | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 34.61 | 55.13 |
| Support Level | $5.08 | $29.95 |
| Resistance Level | $5.37 | $35.38 |
| Average True Range (ATR) | 0.21 | 2.02 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 0.00 | 71.73 |
Price Performance
Historical ComparisonAbout GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.